Form 4: Exact Sciences CFO Sells Shares Post-Abbott Merger

Exact Sciences' EVP and CFO, Aaron Bloomer, reported the disposition of common stock and restricted stock units following the company's merger with Abbott Laboratories.

Summary

• Aaron Bloomer, Executive Vice President and Chief Financial Officer of Exact Sciences Corporation, reported changes in his beneficial ownership of company securities.
• The transactions occurred on March 23, 2026, coinciding with the effective time of the merger between Exact Sciences Corporation and Abbott Laboratories.
• As a result of the merger, Exact Sciences Corporation became a direct, wholly-owned subsidiary of Abbott Laboratories.
• Each outstanding share of Exact Sciences common stock, along with certain vested performance-based restricted stock units (PSUs) and restricted stock units (RSUs), was converted into the right to receive $105.00 in cash per share.
• Bloomer disposed of 138,679 shares of common stock held directly.
• Bloomer disposed of 417 shares of common stock held indirectly in a 401(k) Plan.
• 89,911 shares of common stock were acquired (resulting from the vesting of PSUs based on actual achievement as of November 19, 2025) and immediately disposed of for cash.
• 4,395 Restricted Stock Units (granted before November 19, 2025) vested fully and were converted into the right to receive $105.00 cash per unit.
• 28,063 Restricted Stock Units (granted on or after November 19, 2025) were assumed by Abbott Laboratories and converted into Abbott restricted stock units, maintaining substantially similar terms and conditions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive event for Exact Sciences shareholders, as it represents the successful completion of a merger at a specified cash value, providing liquidity and a premium. The continuity of equity incentives for management through Abbott RSUs is also a positive for talent retention.

Positives

• The successful completion of the merger with Abbott Laboratories provides a clear strategic outcome for Exact Sciences and its shareholders.
• Shareholders, including the reporting person, received a cash consideration of $105.00 per share for their common stock and certain vested equity awards, providing liquidity and a defined return.
• Certain unvested Restricted Stock Units were assumed by Abbott Laboratories, ensuring continuity of equity incentives for the reporting person within the new parent company structure.

Negatives

• Exact Sciences Corporation's common stock is no longer publicly traded, removing it as an independent investment opportunity for public market investors.
• The reporting person's direct and indirect equity holdings in Exact Sciences were fully liquidated for cash, ending their direct ownership stake in the former public entity.

Future Outlook

The filing indicates that Exact Sciences Corporation has become a wholly-owned subsidiary of Abbott Laboratories, implying its future operations and financial performance will be integrated into Abbott's reporting. Certain equity awards for management have been converted into Abbott restricted stock units, aligning their future incentives with the parent company.

Industry Context

StockSavvy.ai notes that this merger signifies a consolidation within the diagnostics and medical technology sector, with a larger player like Abbott acquiring a specialized company like Exact Sciences. Such transactions often aim to leverage complementary technologies, expand market reach, and achieve operational synergies. The cash consideration of $105.00 per share reflects the valuation agreed upon in the merger, which would have been influenced by Exact Sciences' market position, growth prospects, and intellectual property in areas like cancer screening.

Comparison to Industry Standards

• The cash consideration of $105.00 per share for Exact Sciences (EXAS) common stock is a specific valuation for this acquisition. Comparing it to recent M&A deals in the diagnostics sector, such as Roche's acquisition of GenMark Diagnostics ($1.8 billion, $24.05/share) or Danaher's acquisition of Aldevron ($9.6 billion), would require a detailed analysis of revenue multiples, EBITDA multiples, and strategic premiums paid, considering the specific growth profiles and market positions of the acquired entities. Without further financial details of the companies involved, a direct apples-to-apples comparison of the per-share price is not fully indicative of industry standard valuation.
• The structure of converting existing equity awards (PSUs, RSUs) into cash or equivalent awards in the acquiring company (Abbott) is a standard practice in M&A transactions to ensure continuity of incentives and fair treatment of employee equity.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $105.00 cash per share, providing a definitive return on investment and liquidity.
• Employees: Exact Sciences employees, including management, are now part of Abbott Laboratories. Those with unvested equity awards (like some of Bloomer's RSUs) had them converted into Abbott awards, maintaining incentives.
• Customers: Likely minimal immediate impact, but potential for enhanced product offerings or integration with Abbott's broader portfolio in the future.
• Creditors: Exact Sciences' debt obligations would now be backed by Abbott Laboratories, potentially improving credit quality.

Next Steps

• Integration of Exact Sciences' operations and financial reporting into Abbott Laboratories.
• Continued vesting of assumed Restricted Stock Units for Aaron Bloomer as an Abbott employee.

Key Dates

Keywords

Exact Sciences, EXAS, Abbott Laboratories, Merger, Form 4, Insider Transaction, Stock Disposition, Restricted Stock Units, Performance Stock Units, Aaron Bloomer, CFO, Corporate Action